Wells Fargo’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-66,500
| Closed | -$1.02M | – | 7362 |
|
|
2025
Q1 | $1.02M | Sell |
66,500
-44,500
| -40% | -$795K | ﹤0.01% | 3642 |
|
|
2024
Q4 | $2.45M | Sell |
111,000
-64,000
| -37% | -$1.16M | ﹤0.01% | 3045 |
|
|
2024
Q3 | $3.15M | Buy |
+175,000
| New | +$3.06M | ﹤0.01% | 2721 |
|
|
2023
Q2 | – | Sell |
-250,000
| Closed | -$2.21M | – | 7694 |
|
|
2023
Q1 | $2.21M | Hold |
250,000
| – | – | ﹤0.01% | 2782 |
|
|
2022
Q4 | $2.28M | Buy |
+250,000
| New | +$2.18M | ﹤0.01% | 2685 |
|
|
2021
Q3 | – | Sell |
-191,100
| Closed | -$1.89M | – | 7513 |
|
|
2021
Q2 | $1.89M | Buy |
+191,100
| New | +$2.02M | ﹤0.01% | 3732 |
|
|
2021
Q1 | – | Sell |
-200,000
| Closed | -$185K | – | 7365 |
|
|
2020
Q4 | $185K | Buy |
+200,000
| New | +$1.92M | ﹤0.01% | 5117 |
|
|
2020
Q2 | – | Sell |
-972,500
| Closed | -$1.73M | – | 6815 |
|
|
2020
Q1 | $1.73M | Buy |
972,500
+12,200
| +1% | +$125K | ﹤0.01% | 3131 |
|
|
2019
Q4 | $210K | Buy |
960,300
+770,700
| +406% | +$6.88M | ﹤0.01% | 4925 |
|
|
2019
Q3 | $271K | Buy |
+189,600
| New | +$1.45M | ﹤0.01% | 4774 |
|
|
2019
Q1 | – | Sell |
-142,500
| Closed | -$23K | – | 6442 |
|
|
2018
Q4 | $23K | Buy |
142,500
+42,500
| +43% | +$871K | ﹤0.01% | 5749 |
|
|
2018
Q3 | $54K | Buy |
100,000
+50,000
| +100% | +$1.16M | ﹤0.01% | 5572 |
|
|
2018
Q2 | $8K | Sell |
50,000
-100,000
| -67% | -$2.04M | ﹤0.01% | 6008 |
|
|
2018
Q1 | $143K | Buy |
+150,000
| New | +$2.93M | ﹤0.01% | 5153 |
|
|
2017
Q4 | – | Sell |
-92,500
| Closed | -$1.99M | – | 6520 |
|
|
2017
Q3 | $1.99M | Hold |
92,500
| – | – | ﹤0.01% | 3320 |
|
|
2017
Q2 | $669K | Sell |
92,500
-500
| -0.5% | -$15.5K | ﹤0.01% | 4027 |
|
|
2017
Q1 | $807K | Sell |
93,000
-25,400
| -21% | -$867K | ﹤0.01% | 3907 |
|
|
2016
Q4 | $663K | Buy |
118,400
+118,000
| +29,500% | +$4.71M | ﹤0.01% | 4013 |
|
|
2016
Q3 | $1K | Sell |
400
-404,000
| -100% | -$21.1M | ﹤0.01% | 6121 |
|
|
2016
Q2 | $2.33M | Buy |
+404,400
| New | +$21.5M | ﹤0.01% | 2856 |
|
|
2016
Q1 | – | Sell |
-75,000
| Closed | -$3K | – | 6418 |
|
|
2015
Q4 | $3K | Hold |
75,000
| – | – | ﹤0.01% | 5976 |
|
|
2015
Q3 | $234K | Sell |
75,000
-80,000
| -52% | -$5.19M | ﹤0.01% | 4378 |
|
|
2015
Q2 | $672K | Buy |
+155,000
| New | +$9.56M | ﹤0.01% | 3902 |
|
|
2014
Q4 | – | Sell |
-100,000
| Closed | -$913K | – | 6405 |
|
|
2014
Q3 | $913K | Buy |
+100,000
| New | +$5.3M | ﹤0.01% | 3530 |
|
|
2014
Q1 | – | Sell |
-700
| Closed | -$1K | – | 6068 |
|
|
2013
Q4 | $1K | Buy |
+700
| New | +$27.6K | ﹤0.01% | 5639 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
Wells Fargo's TEVA Position: Q1 2026 in Review
Wells Fargo reduced its Teva Pharmaceuticals (TEVA) stake by 25% in Q1 2026, selling an estimated $5.17M and leaving 487,018 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1735.
Wells Fargo first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $183M in Q1 2015. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.
- Wells Fargo held 487,018 shares of Teva Pharmaceuticals worth $14.7M as of Q1 2026.
- Wells Fargo sold 160,835 Teva Pharmaceuticals shares in Q1 2026, an estimated $5.17M.
- Teva Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #1735 holding.
- Wells Fargo first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Wells Fargo's Teva Pharmaceuticals position peaked at $183M in Q1 2015.
- 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.